1 Serological diagnostic kit of SARS-CoV-2 antibodies using CHO-

2 expressed full-length SARS-CoV-2 S1 proteins

3 Rongqing Zhao^{a,1}, Maohua Li^{b,1}, Hao Song^{c,1}, Jianxin Chen^d, Wenlin Ren^b,

4 Yingmei Feng^e, Jinwen Song^f, Ya Peng^c, Bin Su^e, Xianghua Guo^e, Yanjun

5 Wang^k, Jingong Chen^d, Jianli Li^b, Hunter Sun^a, Zhonghu Bai^g, WenJing

6 Cao^h, Jin Zhuⁱ, Qinlu Zhang^j, Yufei Sun^a, Sean Sun^a, Xinkun Mao^a, Junchi

7 Su^a, Hui Chen^g, Ailiang He^d, Ronghua Jin^e*, Le Sun^{a,b}*.

8 ^aAnyGo Technology Co., Ltd, D1117 New China International Square, 89

- 9 Dayangfang Rd, Beijing, China; ^bAbMax Biotechnology Co., LTD, 99 Kechuang 14th
- 10 St., BDA, Beijing, China; ^c Research Network of Immunity and Health (RNIH), Beijing
- 11 Institutes of Life Science, Chinese Academy of Sciences, Beijing, China; ^dZhenge
- 12 Biotechnology Co., LTD, Shanghai, China; ^eBeijing You an Hospital, Capital Medical
- 13 University, Beijing, China; ^fTreatment & Research Center for Infectious Diseases, The
- 14 Fifth Medical Center of PLA General Hospital, National Clinical Research Center for
- 15 Infectious Diseases, Beijing, China;⁸School of Biotechnology, Jiangnan Univ., 1800
- 16 Lihu Ave., Wuxi, Jiangsu, China; ^hBengbu Medical University, Bengbu, Anhui,
- 17 China;ⁱDept. Laboratory, Quzhou People's Hospital, Quzhou, Zhejiang, China;
- ¹⁸ ^jShaanXi Provincial Engineering Research Center for Nano-BioMedical Detection, 3-
- 19 10402A, 2 Zhang Ba Wu Rd., Xi'an, Shaanxi, China; ^kBeijing Institute of Hepatology,
- 20 Beijing, China.
- 21 1.RQ.Z., MH.L. and H.S. contributed equally to the study as the co-first authors.
- 22 *Co-corresponding Authors:
- 23 Le Sun, Ph.D. Email: <u>sunL@antibodychina.com</u>. AnyGo Technology Co., Ltd, D1117
- 24 New China International Square, 89 Dayangfang Rd, Beijing 100122, China.
- 25 Ronghua Jin, Ph.D. Email: <u>93353503@qq.com</u>. Beijing You an Hospital, Capital
- 26 Medical University, Beijing 100069, China
- 27

Serological diagnostic kit of SARS-CoV-2 antibodies using CHO expressed full-length SARS-CoV-2 S1 proteins

30	WHO has declared COVID-19 a pandemic with more than 300,000 confirmed
31	cases and more than 14,000 deaths. There is urgent need for accurate and rapid
32	diagnostic kits. Here we report the development and validation of a COVID-
33	19/SARS-CoV-2 S1 serology ELISA kit for the detection of total anti-virus
34	antibody (IgG+IgM) titers in sera from either the general population or patients
35	suspected to be infected. For indirect ELISA, CHO-expressed recombinant full
36	length SARS-CoV-2-S1 protein with 6*His tag was used as the coating antigen to
37	capture the SARS-CoV-2-S1 antibodies specifically. The specificity of the
38	ELISA kit was determined to be 97.5%, as examined against total 412 normal
39	human sera including 257 samples collected prior to the outbreak and 155
40	collected during the outbreak. The sensitivity of the ELISA kit was determined to
41	be 97.5% by testing against 69 samples from hospitalized and/or recovered
42	COVID-19 patients. The overall accuracy rate reached 97.3%. Most importantly,
43	in one case study, the ELISA test kit was able to identify an infected person who
44	had previously been quarantined for 14 days after coming into contact with a
45	confirmed COVID-19 patient, and discharged after testing negative twice by
46	nucleic acid test. With the assays developed here, we can screen millions of
47	medical staffs in the hospitals and people in residential complex, schools, public
48	transportations, and business parks in the epidemic centers of the outbreaks to
49	fish out the "innocent viral spreaders", and help to stop the further spreading of
50	the virus.

51 Keywords: SARS-CoV-2, COVID-19, Serological assay for SARS-CoV2
52 antibodies.

53 Introduction

As of March 24, there were 370,416 confirmed cases of COVID-19 with 16,324 deaths in the world¹. Infections among healthcare providers were even more alarming, with 4826 Italian doctors and nurses reported to be infected over such a short period due to the lack of appropriate medical protection gear and quick screening of SARS-CoV-2 infections^{2,3}. Making the issue even worse, the virus can be widely transmitted by

59	asymptomatic viral-carriers to people in close contact ⁴ , with some patients reportedly
60	becoming sick once again after their initial recovery and yielding a positive NAT test ⁵ .
61	There is an urgent need to develop rapid, fast and simple screening tools to find
62	"moving viral carriers" and quarantine them.
63	Nucleic acid tests (NAT), the most widely used diagnostic assay for COVID-19
64	in the world, only have a 40% accuracy rate, leading to many patients who test negative
65	on NAT to nonetheless go on to suffer severe complications, including possible
66	mortality, due to undetected SARS-CoV-2 infections ^{6,7} .
67	SARS-CoV-2 is one of the seven human coronaviruses known to infect human.
68	Out of the seven members, SARS, MERS and SARS-CoV-2 have mortality rates
69	between 9-14%, while the other four members, HCoV-OC43, HCoV-NL63, HCoV-
70	229E and HCoV-HKU1, only cause mild flu syndrome and have been around for many
71	years. SARS-CoV-2 contains nucleoprotein (N-protein), spike glycoprotein (S-protein),
72	envelope protein (E-protein) and membrane protein (M-protein) ^{8,9} . SARS-CoV-2's N
73	protein shared over 90% homology with other members of the coronavirus family.
74	Cross-reactivity among N proteins of human coronaviruses was reported by Yu's
75	group ¹⁰ . The S-protein can be divided into two parts: S1 and S2 proteins. The S1 protein
76	attaches the virion to the cell membrane by interacting with a host receptor (human
77	ACE2), initiating the infection ¹¹ . SARS-CoV-2's S1 protein has 685 amino acids with
78	seven potential glycosylation sites ¹² . No evidence of strong cross-reactivity was
79	observed with many neutralizing SARS or MERS monoclonal antibodies (personal
80	communications), suggesting it has very unique antigenicity.
81	Several diagnostic kits for measuring SARS-CoV-2 IgM and IgG have been
82	approved by Chinese FDA with the restriction that they may only be used as companion
83	tests for NAT, and not to be used for general screening of SARS-CoV2 infection due to

84	lacking the required specificity and sensitivity. Possible cause may be the poor quality
85	of the detecting antigens used. Three different types of antigens were reported to be
86	used: 1) the recombinant N protein from SARS-CoV-2, which is highly conserved
87	among all 7 members of coronaviruses and led to poor specificity in tests of general
88	population, 2) CHO-expressed S1 protein from SARS-CoV-2, which has very different
89	antigenicity from its counterpart in SARS-CoV-2, or 3) the receptor binding domain
90	(RBD) of SARS-CoV-2 S1, which is about 200 amino acids long with only one
91	glycosylation, compared to the full length S1 which has 7 glycosylation sites. These
92	latter two can result in poor sensitivities. Misdiagnose of HCoV-OC43, HCoV-NL63,
93	HCoV-229E and HCoV-HKU1infections as SARS-CoV-2 could send thousands and
94	thousands of people to already over-loaded hospitals and increase the risk of real
95	infection by SARS-CoV-2 during the unnecessary hospital visit. On the other hand,
96	missed detections of SARS-CoV-2 infections can deny patients the opportunity to
97	receive early preventative care before the disease progresses into acute respiratory
98	syndrome, which has an over 60% mortality rate. Therefore, it is extremely important to
99	develop serological tests using the right detecting antigen: fully glycosylated, full length
100	SARS-CoV-2 S1 recombinant protein(s).
101	The full length SARS-CoV-2 S1 protein has previously been difficult to express
102	at a commercially viable level (personal communications), but using our patented
103	technology, we have improved the expression level by close to a hundred fold
104	(~80mg/L) using either CHO or 293F mammalian cells. Using the CHO-expressed
105	SARS-CoV-2 S1 protein as the detecting antigens, we have developed a very sensitive
106	and highly specific diagnostic assay for screening the health care staff at the hospitals to
107	reduce the in-hospital infections, and checking the in-coming visitors from the epidemic

- 108 areas, and the work forces coming back to work, and the general populations for SARS-
- 109 CoV-2 viral infection.

110 Materials and methods

111 Regents and supplies

112 Freund's complete adjuvant (CFA), Freund's incomplete adjuvant (IFA), Polyethylene

113 glycol 4000 (PEG4000), DMSO, TMB substrates were purchased from SIGMA, USA.

114 High-binding 96-well ELISA plates were purchased from Corning, USA. L-glutamine,

- antibiotics. ELISA buffers and solutions were prepared using analytic reagent-grade
- 116 chemicals unless specified otherwise. Goat anti-human IgG (H+L) peroxidase conjugate
- 117 was sourced from Jackson Immunoresearch, USA. Cynomolgus monkeys were hosted
- 118 at Xierxing Biotech., Beijing, China. Mouse anti-His 6X mAb 6E2 was provided by
- 119 AbMax. HEK 293F cells and CHO cells and culture media were provided by Zhenge
- 120 Biotech., Shanghai, China. SDS-PAGE precast gels were purchased from GenScript,
- 121 China.

122 Protein expression and purification

123 The full length SRARS-CoV-2 S1 gene (GenBank: QIC53204.1) with C terminal were 124 synthesized by GENEWIZ, China, and inserted into mammalian cell expression vectors 125 with either 6*His tag or fused with human IgG Fc. The purified plasmid DNA was used 126 to transfect mammalian CHO and human 293F cells by lipofection using liposome 127 transfection kit (Invitrogen, USA) following manufacturer's instructions. The 128 transfected mammalian cells were grown at 37°C and 5% CO₂ for a few days prior to 129 harvesting. The harvested cells were pelleted by centrifugation at 4,000 rpm for 10 130 minutes. The recombinant S1-His6X protein was by immobilized metal affinity

- 131 chromatography. The recombinant S1-Fc protein was purified by Protein A
- 132 chromatography. Protein concentration was determined by OD absorbance at 280nm.
- 133 The purity and identity of the purified recombinant SRAR-CoV-2 S1 proteins were
- 134 ascertained by SDS-PAGE, Coomassie brilliant blue staining and ELISA with anti-
- 135 6*His mAb. Briefly, the samples were loaded onto 12% gels, separated by SDS-PAGE,
- 136 either stained with Coomassie brilliant blue staining for purity.

137 Generation of monkey polyclonal antibodies

- 138 10 months-old Cynomolgus monkeys were first immunized with CHO-expressed S1-Fc
- 139 fusion protein in Complete Freund's Adjuvant and boosted in Incomplete Freund's
- 140 Adjuvant. Two to four weeks after the first immunization, bleeds were tested for titers
- 141 by indirect Enzyme-linked Immunoassay (ELISA).

142 Serum samples for assay

143 The protocols were approved by the institutional ethical committee of Beijing You An 144 Hospital, Capital Medical University. Strong negative plasma samples and negative 145 ones were obtained from human subjects that were collected prior to and during the 146 COVID-19 outbreak respectively. Plasma samples were also obtained from hospitalized 147 and/or recovered patients confirmed SARS-CoV-2 virus infection. Informed consent 148 was obtained from all the human subjects who participated in the study after the nature 149 and possible consequences of this study had been fully explained and the protocols were 150 approved by the institutional ethical committee. The serum samples were inactivated at 151 56 °C for 30 min and stored at -20 °C until used.

152 SARS-CoV-2 virus serology ELISA kit

153 Briefly, known amount of recombinant full length SARS-CoV-2 S1-His was diluted in

154	PBS (10 mM, pH 7.4) and 100 μ L of the solution was added to each well of 96-well
155	high binding ELISA plates (8 wells/strip, Corning, USA) and incubated overnight at 2-
156	8°C. The wells were emptied and washed twice with PBS and unsaturated sites were
157	blocked with 3% BSA in PBS by incubating for 1 hour at room temperature. Coated
158	plates were air-dried and sealed in plastic bags and stored at 2-8°C until used.
159	Anti-SARS-CoV-2 S1-Fc monkey pAbs or human plasma sample were first
160	diluted in negative human sera (pooled serum from 8 human subjects prior to the
161	outbreak of COVID-19). For ELISA, each serum sample was tested in duplicates and 46
162	samples can be accommodated on one plate. Prior to test, human samples or the
163	standards were diluted 1:20 in sample dilution buffer, such as 20% Calf-serum (CS) in
164	PBS. 100 μ L of appropriately diluted sample was added to each well of the S1-His-
165	coated plates and incubated for 1 hour at 37°C with constant shaking. The wells were
166	emptied and washed twice with PBS containing 0.1% Tween 20 (PBST). 100 μL of
167	appropriately diluted goat anti-human IgG (H+L) peroxidase conjugate in 20%CS in
168	PBS was added to the respective wells and incubated for another 1 hour at 37°C with
169	constant shaking. The wells were emptied and washed five times with PBST before
170	addition of TMB substrate solutions. The chromogenic development was stopped using
171	$0.1M H_2SO_4$ after 15 minutes of incubation in the dark. Optical density (OD) was
172	measured at 450nm wave length in a microplate spectrophotometer (Thermo Scientific,
173	Multiskan MK3).
174	Calculate the mean value (AVG1) of Negative control, and times the lot-specific
175	converting factor (CF) as the negative cut-off point (N-Cut); calculate the mean value
176	(AVG2) of Weak positive control, use AVG2 as the positive cut-off point (P-Cut). If the
177	absorbance value of the sample is greater than or equal to the positive cut-off point (P-
178	Cut), the result of the sample is positive, indicating that the sample has detected

antibodies that recognize the SARS-CoV-2; if the absorbance value of the sample is less than the negative cut-off point (N-Cut), the result of the sample is negative, it means that no antibody that recognizes the SARS-CoV-2 is detected in the sample; if the absorbance value of the sample is less than the positive critical point value (P-Cut) and greater than or equal to the negative critical point value (N-Cut), the result of the sample falls into a grey area and needs further experimental confirmation.

185 **Results**

186 Construction, expression and purification of recombinant SARS-CoV2 S1

187 proteins

188 The Spike protein S1 plays a key role in virus binding and entering host cells via human

ACE2. It has 685 amino acids with 7 potential glycosylation sites, and its heavy

190 glycosylation made it with very distinguishable antigenicity from its close family

191 members SARS and MERS, demonstrated by the no significant cross reactivity was

192 observed with existing neutralizing mAbs to SARS or MERS. The DNA sequence

193 corresponding to the full length SARS-CoV-2 S1 protein was chemically synthesized

and inserted into two different mammalian cell expression vectors with either 6XHis tag

195 or human IgG Fc region to produce two versions of recombinant SARS-CoV-2 proteins,

196 S1-His and S1-Fc (Fig. 1A).

197 Culture supernatants were purified using either Ni column or Protein A column.

198 As shown in Fig.1B, a defused band was observed around 120 kD in elution (Lane 5

and 6), which is much larger than the expected size of S1-His, suggesting heavy

200 glycosylation took place. Two sharp bands at 500 kD or higher were detected in the

201 elution of Protein A column (Fig. 1C), representing dimer and oligomer of S1-Fc.

Multiple batches of expressions and purifications of both S1-His and S1-Fc recombinant proteins using two mammalian cell systems have been carried out. The culture supernatants and cell lysates were collected at different times and the expression levels were examined by ELISA using mouse anti 6*His tag mAb 6E2. Using our patented technology, the transient expression levels of S1-His and S1-Fc in either CHO cells or 293F cells reached 30-72mg/L (Table S1). Stable cell lines just established recently.

209 Characterization of the purified recombinant SARS-CoV-2 S1 proteins

210 To verify the true identity, the purified recombinant S1-His protein was coated on to 96-

211 well plate and examined with the plasma samples collected from recovered COVID-19

212 patients. As shown in Fig. 2A, all six plasma samples reacted strongly with the purified

213 recombinant SARS-CoV-2 S1 protein, indicating not only the right sequence but also

the correct conformation.

To generate the positive controls for the COVID-19 serological assays, two monkeys were immunized with recombinant S1-Fc with the help of adjuvant. As shown in Fig. 2B, on day 16, both monkeys developed very strong immune reactivity against S1-His, with titers at 1:200 for the male monkey and 1:800 for the female one. The two sera were mixed and used to spike the human normal sera for preparation of the positive controls.

221 Development of Serological assays for SARS-CoV-2 antibodies.

222 To evaluate the effect of S1-His protein coating concentrations for capturing anti-

223 SARS-CoV-2 antibodies in testing samples, each well of 96-well EIA plate was coated

with 100 µL of S1-His protein at eight different concentrations (0.1, 0.2, 0.4, 0.5, 0.8,

225 1.0, 1.2 and 1.5 μg/mL) in 10mM PBS pH 7.4 at 2-8°C overnight.

226 The solid phase-bound S1-His protein was probed using appropriately diluted 227 mouse anti-S1-His mAb 6E2 (0, 2, 5, 20 μ g/mL). As shown in Table S2, at all eight 228 different coating concentrations of S1-His, the OD values showed dose dependency, 229 while the maximal OD values increased with increasing coating concentrations of S1-230 His protein. Since the background OD values did not change significantly, 1.5µg/mL 231 concentration of S1-His protein was considered optimal for coating of ELISA plate for 232 kit manufacture to ensure the highest sensitivity. 233 There is a need to dilute testing human sera since matrix components, especially 234 the host antibodies, can contribute to high assay background if undiluted. A set of 8 235 strong negative plasma samples (collected prior to the outbreak of COVID-19) were 236 tested at five different dilutions to experimentally determine the assay's optimal 237 dilution. 238 As shown in Table S3, if the dilution is not high enough, such as 1:5 or 1:10, the 239 background is too high. At 1:20 or higher dilutions, the background was acceptable. 240 Base on suggestions from the clinicians, 1:20 dilution is more practical and determined 241 to be the dilution rate for future use. 242 To balance between preservation of the detection of weak affinity SARS-CoV-2 243 antibodies and reduction of background, we have tried different washing, sample 244 dilution and enzyme dilution buffers. 245 Addition of detergent for sure will reduce the non-specific binding of antibodies 246 binding to the plates, but too much of it will also remove some of the blocking of the 247 plate and give more opportunity for non-specific binding. As you can see from Fig. 3A, 248 with detergent Tween-20 in the washing buffers, the background was significantly 249 reduced.

250 We also examined the influences of the sample dilution buffers, enzyme dilution 251 buffers and assay conditions on the performance of the tests. Human plasma or serum 252 contains extremely high level of antibodies which will non-specifically bind to the wells 253 and could potentially increase the background significantly. One approach is to use non-254 human sera, such as calf-serum (CS), to compete for the non-specific binding. In this 255 study, we tested both 3% BSA-PBS and 20% CS-PBS as the sample dilution buffers 256 against 8 normal human plasma samples, the human negative control, the strong human 257 negative control and human sera spiked with various amounts of sera from SARS-CoV-258 2 S1-Fc immunized monkeys. In the same experiment, we also tried the incubation with 259 or without the constant shaking. As shown in Fig. 3B & 3C, 20%CS-PBS significantly 260 reduced the background, comparing to 3% BSA-PBS, with much better signal-to-noise 261 (S/N) ratio. Although taping the plates every 10 minutes produced similar results as 262 constant shaking, it is still highly recommended to use temperature controlled 263 microplate shaker. 264 Based on above data, the best manufacturing and key testing parameters for the 265 SARS-CoV-2 serological ELISA kit were selected as 1) 1.5µg/mL SARS-CoV2 S1-His 266 for plate coating, 2) 1:20 dilution of human sera using 20% CS-PBS as sample and 267 enzyme diluent, 3) incubation with constant rotation using a temperature controlled 268 micro-plate shaker.

269 Reproducibility: Intra-assay and inter-assay precisions

Several batches of the SARS-CoV2 serology ELISA kits were manufactured at three
different locations, and were tested using positive monkey sera at different dilutions in
human sera for assessing the reproducibility of manufacturing and assay precisions.

Summarized in Table S4, all three batch's Intra-CVs were in the range of 6.3912.05%, which is within the acceptable criterion of less than or equal to 15%. The intraassay imprecision of samples (CV) was around 10.38%.

276 Specificity of the serological ELISA assay

277 The diagnostic specificity of the kit was demonstrated by testing 412 human samples

278 including 257 samples collected prior to (strong negatives) and 155 samples collected

during (negatives) the outbreak of COVID-19.

As shown in Table 1, for the strong negatives, obtained from different sources

281 including 48 samples from Rabies vaccinated patients, showed very similar specificities

between 95.6-100%. In the group of Commercial #2, they were from 50 Blacks, 30

283 Whites, 24 Asian females and 20 Asian males, and no significant difference in

background was observed between different races or genders. The specificity for strong

negative was determined at 96.9%.

For the negatives, group #1 was collected from Beijing, and groups #2-4 were

287 collected from Zhejiang province, both areas have confirmed COVID-19 cases. In the

initial test, 2 of the 15 samples from Beijing's group were tested antibody-positive

289 (Table 1). We performed the antigen competition assay using the rec. S1-His proteins at

290 very high concentrations, and found that the signals could not be blocked, suggesting

those two were false negatives. No positive was detected in the other three groups. The

specificity was 98.7%. Combine the data from the strong negative samples, the overall

specificity of the ELISA kit was 97.5% (402/412).

294 Sensitivity of the serological ELISA assay

295 In collaboration with Chinese CDC, the ELISA kits were sent to several hospitals

including two in Beijing and one in Wuhan to examine its sensitivity against the real

297	clinic samples. Some of the data were presented in Fig. 4A-D. One study group
298	encompass of 45 clinic samples from COVID-19 confirmed patients at different clinic
299	stages at different ages with different genders. As shown in Fig. 4A, out of the 45
300	samples, 44 tested positive for SARS-CoV2 antibodies with a sensitivity of 97.7%.
301	There were 21 samples (one on day-1, 3 on day-3, 7 each on days-4 and -5, 2 on day-6
302	and 1 on day-7) collected within one week of onset of COVID-19 diseases, all of them
303	tested positive for SARS-CoV-2. So far, no significant difference in antibody levels
304	observed between different genders or ages (Fig. 4B & 4C).
305	In another group of study, shown in Fig. 4D, 23 out of 24 clinic samples were
306	tested positive for SARS-CoV-2 antibodies. We sort the samples by collecting time 1)
307	one day after hospitalization (Hosp-Day 1), 2) anytime during the hospitalization
308	(Hospitalized), 3) follow-up on day 14 post-release from the hospital (Follow-14).
309	Clearly, the ones just arrived at the hospital had the lowest levels of SARS-CoV-2
310	antibodies. The antibody levels increased during the treatments and after been released
311	from the hospitals. More works will be carried out to exam the levels of IgG and IgM of
312	those positive samples respectively by simply changing the goat-anti-human IgG (H+L)
313	secondary antibodies, which will detect both IgG and IgM, to goat-anti-human IgG Fc
314	specific secondary antibodies and mouse anti-human μ Chain-specific mAb.
315	As summarized in Table 2, the overall sensitivity of the serological assay for
316	SARS-CoV2 total antibodies was 97.1%.
317	Using the assay as screening tool for epidemiology study, in one case, there
318	were five persons who were in close contact of confirmed COVID-19 patients and they
319	had been quarantine for 14 days, showed no sign of sickness, tested negative twice by
320	NAT and were released. One of them was tested positive for SARS-CoV-2 by this

321 serological ELISA kit. This ELISA assay may offer a tool for the CDC teams who

322 stayed in WuHan to search the clues for those new COVID-19 cases surfaced recently

323 who had no clear connection with any confirmed COVID-19 patients.

324 Discussion

325 The S1 protein binds to ACE2 protein on the surface of the human cells and plays 326 critical role in virus infection. Our data showed that the S1 protein of SARS-CoV-2 327 virus is heavily glycosylated, evidenced by the purified S1-His protein which had an 328 apparent molecular weight of 120 kD on SDS-PAGE gel, while its calculated molecular 329 weight should be just around 70 kD. Glycosylation not only help the protein folding 330 correctly, but also contribute greatly to protein's affinity to its receptor. For example, 331 the binding affinity of IgG1 to FcyRs on effector cell surfaces is highly dependent on the N-linked glycan at asparagine 297 (N297) in its CH2 domain^{14,15}, with a loss of 332 binding to the FcyRs observed in N297A point mutants^{16,17}. Even the nature of the 333 334 carbohydrate attached to N297 modulates the affinity of the FcyR interaction as well^{18,19}. 335

336 In this study, full-length SARS-CoV-2 S1 proteins were expressed using both 337 human 293F cells and Chinese hamster ovarian cells to ensure the recombinant proteins 338 have the correct glycosylation profiles to resemble the native conformation on the 339 surface of virus. Using our patented technology, we have successfully increased the 340 expression levels of the full length recombinant SARS-CoV-2 S1 proteins up to 341 70mg/L. Using the CHO cell expressed full length SARS-CoV-2 S1-His protein as the 342 capturing antigen, we have been able to develop a COVID-19 serological ELISA kit 343 with high specificity (97.5%) and great sensitivity (97.1%). With an accuracy of 97.3%, 344 the assay we developed here will be well suited for screening the health care staff to 345 reduce in-hospital transfection of SARS-CoV-2 virus. Rapid Immunochromatographic 346 Assay (RICA) was also developed using a double antigens Sandwich format. It is now

347	in clinic	study t	for its s	pecificity	and sensitivity	y. Once f	inished,	we will have	another

- tool to help patients to test at home so they either can receive early preventative care
- 349 before the disease progresses into acute respiratory syndrome or not making un-
- 350 necessary hospital visits for regular flu.

351 Author contributions

- 352 RQZ, MHL, WLR, JXC, JGC, JLL, ALH contributed the development of recombinant
- 353 proteins and assay development. WLR, YFS, ZHB, ZYS, QLZ, XKM, JCS, HC
- 354 contributed in the pilot productions of assay kits. HS, YMF, XHG, JWS, YP, BS, YJW,
- 355 WJC, JZ contributed the clinic studies. HS, SS contributed in market studies and
- 356 technical writing.

357 Acknowledgements

- 358 This work is supported by Research Grants from Beijing Science and Technology
- 359 Commission, and Bill & Melinda Gates Foundation to Le Sun. This work was also
- 360 supported by the National Natural Science Foundation of China (NSFC) (81702015),
- and the National Science and Technology Major Project (2018ZX10733403) to H.S. We
- 362 thank Professor Wenjie Tan from National Institute for Viral Disease Control and
- 363 Prevention, Chinese Center for Disease Control and Prevention for providing the
- 364 sequences of SARS-CoV-2 S1 protien.

365 **References**

- 366 1. "Reports of COVID-19 Pandemics, Confirmed cases and deaths in and outside of China."
 367 www.163.com Mar. 24, 2020.
- 368 2. "Surging health care worker quarantines raise concerns as coronavirus spreads"
 369 www.khn.org Mar. 10, 2020.
- 370 3. "Thousands of medical staff infected by coronavirus in Italy" Gruppo Italiano per la
 371 Medicina Basata sulle Evidenze, Mar. 18, 2020.

- 372 4. "New cases of COVID-19 patients with no direct connections to confirmed patients
 373 surfaced at the clinics in Wuhan, a danger sign!" Health Daily, Mar. 17, 2020.
- 374 5. "Three members from the same family sick and NAT positive again. Expert cautioned
 375 maybe "false-cure". Health Daily Mar. 21, 2020.
- 376 6. "Field Experts answered NAT will not be the only diagnose evidence" People's Daily, Feb.377 9, 2020.
- 378 7. "17 year-old Korean boy died of COVID-19 but tested negative in 14 NAT" Korea Central
 379 Daily, Mar. 19, 2020.
- Berlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and
 pathogenesis. Nature reviews. Microbiology 7, 439-450, doi:10.1038/nrmicro2147 (2009).
- 382 9. Stadler, K. et al. SARS--beginning to understand a new virus. Nature reviews.
 383 Microbiology 1, 209-218 (2003).
- 384 10. Yu, F., Le, M. Q., Inoue, S., Thai, H. T. C., Hasebe, F., Del Carmen, P. M. et al. (2005).
- 385 Evaluation of inapparent nosocomial severe acute respiratory syndrome coronavirus
- 386 infection in Vietnam by use of highly specific recombinant truncated nucleocapsid protein-
- based enzyme-linked immunosorbent assay. Clin. Diagn.Lab.Immunol. 12, 848–854.
- 388 11. Stertz, S. et al. The intracellular sites of early replication and budding of SARS389 coronavirus. Virology 361, 304-315, (2007).
- 390 12. Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of
- the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. The
 Journal of biological chemistry 279, 3197-3201 (2004).
- 393 13. Wu,F., Zhao,S., Yu,B., Chen,Y.-M., Wang,W., Hu,Y., Song,Z.-G., Tao,Z.-W., Tian,J.-H.,
- 394 Pei, Y.-Y., Yuan, M.L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L.,
- Holmes,E.C. and Zhang,Y.-Z. A novel coronavirus associated with a respiratory disease in
 Wuhan of Hubei province, China. Unpublished. ACCESSION YP_009724390
- 397 14. Jefferis, R. & Lund, J. Interaction sites on human IgG-Fc for FcgammaR: current models.
 398 Immunology letters 82, 57-65 (2002).
- 399 15. Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M. & Dwek, R.A. The impact of
 400 glycosylation on the biological function and structure of human immunoglobulins. Annual
 401 review of immunology 25, 21-50 (2007).
- 402 16. Shields, R.L. et al. High resolution mapping of the binding site on human IgG1 for Fc
- 403 gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with
- 404 improved binding to the Fc gamma R. The Journal of biological chemistry 276, 6591-6604405 (2001).
- 406 17. Tao, M.H. & Morrison, S.L. Studies of a glycosylated chimeric mouse-human IgG. Role of
 407 carbohydrate in the structure and effector functions mediated by the human IgG constant
 408 region. Journal of immunology 143, 2595-2601 (1989).

- 409 18. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of
- 410 immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
- 411 19. Shields, R.L. et al. Lack of focus on human IgG1 N-linked oligosaccharide improves
- 412 binding to human Fc gamma RIII and antibody-dependent cellular toxicity. The Journal of
- 413 biological chemistry 277, 26733-26740 (2002).

	S	SARS-CoV-2 Ab	SARS-CoV-2 Ab	Sub	G 101 1/	
Groups	Sources	Negative	Positive	Total	Specificity	
	Rabies vaccinated	47	1	48	97.9%	
	Commercial #1	20	0	20	100.0%	
	Commercial #2	119	5	124	96.0%	
Strong Negative	Hospital #3	43	2	45	95.6%	
	Clinical Lab	20	0	20	100.0%	
	Total	249	8	257	96.9%	
	Group #1	13	2	15	86.7%	
Negative	Group #2	9	0	9	100.0%	
	Group #3	123	0	123	100.0%	
	Group #4	8	0	8	100.0%	
	Total	153	2	155	98.7%	

414 Table 1 Specificity and sensitivity assay against strong negative samples

Strong negative Samples were collected from prior to the outbreak of COVID-19 from different
origins, negative samples were collected from during the outbreak of COVID from different
cities of China. SARS-CoV-2 Ab Negative represented no SARS-CoV-2 antibodies were
detected in the sample, SARS-CoV2 Ab Positive represented SARS-CoV-2 antibodies were
detected in the sample.

420 Table 2 Sensitivity assay against positive samples

C	SARS-CoV-2 Ab	SARS-CoV-2 Ab	Sub	Specificity	
Sources	Negative	Positive	Total		
Hospital #1	1	44	45	97.8%	
Hospital #2	1	23	24	95.8%	
Total	2	67	69	97.1%	

421 Positive samples were collected from COVID-19 infected or recovered patients. Two different

422 hospitals completed the test independently. SARS-CoV-2 Ab Negative represented no SARS-CoV-2

- 423 antibodies were detected in the sample, SARS-CoV2 Ab Positive represented SARS-CoV-2
- 424 antibodies were detected in the sample.
- 425

426 Figure 1. Construction and expression of the SARS-CoV-2 S1 protein.

- 427 A) Domain structures of SARS-CoV-2 Spike 1 proteins, including full length spike protein S, S1
- 428 protein with 6*HIS and Fc TAG: the signal peptide was colored with blue or red, S1 domain was
- 429 coloured with yellow, S2 domain was coloured with green, His tag was coloured with light-blue and
- 430 Fc tag was coloured with grey.
- 431 B) SDS-PAGE of S1-His expression and purification: Lane M referred to the MW markers (kDa),
- 432 lane 1 referred to the culture supernatant, lane 2 referred to the flow-through, lane 3 referred to the
- 433 1st wash with buffer 1, lane 4 referred to the 2nd wash with buffer 2, lanes 5~8 referred to three
- 434 different fractions eluted with buffers containing 50 mM MES, 250 mM Imidazole, 150 mM NaCl
- 435 рН 7.4.
- 436 C) SDS-PAGE of S1-Fc expression and purification: Lane M referred to the MW markers (kDa),
- 437 lane 1 referred to the culture supernatant, lanes 2 referred to eluted fractions, lane 3 referred to the
- 438 flow-through.

439 Figure 2. Identification of recombinant S1 protein.

- 440 A) Recombinant S1-HIS protein was coated on the plate and characterized by plasma samples. The
- 441 negative samples represented plasmas from non-infected populations and SARS-CoV-2
- 442 seroconverters indicated plasmas from recovered COVID-19 patients.
- B) Monkey sera after immunization with S1-Fc. Each well was coated with 100 μl of S1-
- 444 His6X at 1 µg/mL, probed with different concentrations of monkey sera prepared in 20% CS-PBS.
- 445 After washes, the immune complexes were detected with Goat anti-Human IgG (H + L) peroxidase
- 446 conjugate (1: 20,000 in 20% CS-PBS). TMB substrate solution was added and OD measured at 450
- 447 nm wave length in a microplate spectrophotometer.

448 Figure 3. Kit optimization for the serological assay.


A) Different washing buffers including PBS and PBST were tested. PBS (0.01M phosphate-salt

450 buffer, pH 7.4), PBST-1 (PBS-0.05% tween-20), and PBST-2 (PBS- 0.1% tween-20).

- 451 B) ~C) Optimization of sample dilution buffer and enzyme dilution buffer.
- 452 Different buffers were chosen for optimization of sample and enzyme dilution buffers by
- 453 negative samples (B) and positive controls (C). 20% CS referred to 20% (v/v) calf serum in
- 454 0.01M phosphate-salt buffer (pH 7.4), 3% BSA referred to 3% (3g/100ml) BSA in 0.01M
- 455 phosphate-salt buffer (pH 7.4), shake referred to 96-well plate with constant shaking at 200rpm,
- 456 and manual mean 96-well plate with manual tapings every 10 minutes.


457 Figure 4. Sensitivity assay of the Kit.

- 458 A) ~C) 45 Plasma samples collected from either hospitalized or recovered COVID-19
- 459 patients were tested with the serological ELISA kit. A) days after onset of diseases, B)
- 460 different genders, C) different age groups.
- 461 D) 24 Plasma samples collected from either hospitalized or recovered COVID-19
- 462 patients, were tested with the serological ELISA kit. The samples were marked by
- 463 collecting time: Hosp-Day 1 were samples collected one day after hospitalization,
- 464 Hospitalized were samples collected anytime during the hospitalization, Follow-14
- 465 follow-up were samples collected on day 14 post-release from the hospital.




В

	Μ	1	2	3	4	5	6	7
250kD	-			-				
130kD	-							
100kD	-					100		
70kD	-	Lu.C		and the second				
55kD	-		Beckered					
		6.0						
35kD	-							
25kD								
20kD								




8



6*His-tag


Fc tag




Negative samples

Α


SARS-CoV-2 Seroconverters






Dilution Rate


A


















Γ

В





Female